"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease."
BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030.
The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa).
This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities.
The factors driving the market's growth include:
High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies.
Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development.
Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report.
Report Synopsis
Report Metric | Details |
Base year considered | 2024 |
Forecast period considered | 2025-2030 |
Base year market size | $235.8 million |
Market size forecast | $13.1 billion |
Growth rate | CAGR of 67.8% for the forecast period of 2025-2030 |
Segments covered | Target Type, Drug Type, Drug Molecule Type, and Region |
Regions covered | North America, Europe, Asia-Pacific, South America, Middle East and Africa |
Market drivers | • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. |
Interesting facts:
- As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules (Clinicaltrials.gov).
- There are very few DMTs targeting the moderate to advanced stages of AD.
Emerging startups:
- AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits.
- TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD.
The report addresses the following questions:
- What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?
- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. - Which market segments are covered in the report?
- Target type, drug, molecule type, and region. - Which target type will be dominant through 2030?
- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. - Which molecule type market is growing the fastest?
- The large molecule segment is the fastest growing market. - What are the key challenges in of the market?
- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs.
Market leaders include:
- ALZHEON INC.
- ANAVEX LIFE SCIENCES CORP.
- ANNOVIS BIO INC.
- BIOGEN
- BIOVIE INC.
- EISAI CO. LTD.
- JOHNSON & JOHNSON
- LILLY
- NOVO NORDISK A/S
- TAURX PHARMACEUTICALS LTD.
Related reports:
Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/5458209/BCC_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alzheimers-dmt-market-to-grow-at-67-8-cagr-through-2030--302528769.html
